Greenbrook TMS completes C$15 million equity offering

On May 21, 2020, Greenbrook TMS Inc. ("Greenbrook") announced the closing of its previously announced public offering of common shares made pursuant to an agency agreement with Bloom Burton Securities Inc. and Clarus Securities Inc., as co-lead agents, Canaccord Genuity Corp., Desjardins Securities Inc. and Stifel GMP.

Pursuant to the offering, Greenbrook issued a total of 9,093,940 common shares at a price of C$1.65 per share for gross proceeds of approximately C$15 million.

Greenbrook intends to use the net proceeds from the offering to fund operating activities and for other working capital and general corporate purposes.

Further information can be found on Business Wire's website.

Greenbrook, operating through 124 company-operated treatment centers, is a leading provider of Transcranial Magnetic Stimulation (TMS), an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States.